1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

Awaiting development [GID-TA11585] Expected publication date: TBC

  • Project information
  • Project documents

30856-Patritumab-Deruxtecan-for-Non-Small-Cell-Lung-Cancer-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)